Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1336-1341

  Amezcua, C A ^a   Macdonald, H R ^a   Lum, C A ^a   Yi, W ^a   Muderspach, L I ^a   Roman, L D ^a   Felix, J C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cytokeratin; Endometrial adenocarcinoma; Immunohistochemistry; Isolated tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN AE1; CYTOKERATIN ANTIBODY;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CELL ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL SYSTEM; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PREVALENCE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; STAINING; TISSUE SECTION; TUMOR CELL;

ADULT; AGED; CARCINOMA; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 33745085464     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00528.x     Document Type: Article

References (14)

1. Creasman WT Morrow CP Bundy BN Homesley HD Graham JE Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 1987 60: 2035 41.
2. Morrow CP Bundy BN Kurman RJ et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol 1991 40: 55 65.
3. Abeler VM Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991 67: 3093 103.
4. Creasman WT Odicino F Maisonneuve P et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001 6: 47 86.
5. Greene FL Page DL Fleming ID Fritz AG Balch CM Haller DG Morrow M., eds. AJCC cancer staging manual, 6th edn. New York: Springer-Verlag, 2002: 223 40.
6. Cote RJ Peterson HF Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastasis in management of breast cancer. Lancet 1999 354: 896 900.
7. Czerniecki BJ Scheff AM Callans LS et al. Immunohistochemistry with pancytokeratin improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999 85: 1098 103.
8. Nahrig JM Richter T Kuhn W et al. Intraoperative examination of sentinel lymph nodes by ultrarapid immunohistochemistry. Breast J 2003 9: 277 81.
9. Naume B Wiedswang G Borgen E et al. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 2004 10: 3091 7.
10. Bosquet JG Keeney GL Mariani A Webb MJ Cliby WA. Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol 2003 91: 518 25.
11. Yabushita H Shimazu M Yamada H et al. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol 2001 80: 139 44.
12. Moore KH Thaler HT Tan LK Borgen PI Cody HS. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biological metastasis or procedural artifact?. Cancer 2004 100: 929 34.
13. Diaz NM Cox CE Ebert M et al. Benign mechanical transport of breast epithelial cells to sentinel lymph nodes. Am J Surg Pathol 2004 28: 1641 5.
14. Lee KR Vacek PM Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol 1994 54: 10 8.